CFTR Mutation Detection Kit for African Populations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for cystic fibrosis (CF) disproportionately disadvantage African and mixed-race patients due to underrepresentation in genetic research and a lack of Afro-centric genetic tests, leading to misdiagnosis and delayed detection of CFTR gene mutations.
Innovation Solution
A method and kit for identifying CFTR gene mutations using nucleic acid sequences complementary to specific segments of the CFTR gene, employing techniques such as ARMS, NGS, qPCR, and microarrays, specifically designed for patients of African origin, allowing for accurate detection and diagnosis of CF and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If European-centric genetic tests are used for CF diagnosis, then mutation detection is efficient for Caucasian patients, but detection accuracy deteriorates for African and mixed-race patients
Solution Approach 1:
The patent develops population-specific genetic test panels tailored to the unique mutation profiles of African and mixed-race patients. Instead of using a universal European-centric panel, the invention creates customized testing protocols that incorporate mutations prevalent in African populations, thereby achieving high detection accuracy for each specific racial group while maintaining overall test versatility through multiple panel options.
Solution Approach 2:
The invention modifies the genetic test parameters including the specific mutations screened, primer sequences, and detection thresholds to match the genetic characteristics of African populations. By changing these test parameters from the standard European protocol, the patent achieves accurate detection of CFTR mutations in African and mixed-race patients without compromising the effectiveness of the diagnostic approach.
2Measurement precision
If comprehensive genetic testing is performed for all populations, then diagnostic accuracy improves, but test complexity and cost increase
Solution Approach 1:
The patent divides the comprehensive genetic testing into segmented, population-specific panels. Rather than implementing a single all-encompassing test that would be overly complex, the invention creates modular test panels tailored to specific racial groups (e.g., African-specific panel, European-specific panel). This segmentation maintains high diagnostic accuracy for each population while reducing overall test complexity through targeted, streamlined protocols.
Solution Approach 2:
The patent applies partial action by implementing testing panels that cover the most prevalent mutations specific to each population rather than attempting to detect every possible mutation globally. For African patients, the panel focuses on mutations commonly found in that population, providing sufficient diagnostic accuracy without the excessive complexity of universal coverage.
3Reliability
If CF diagnosis is excluded based on racial assumptions, then misdiagnosis of non-Caucasian patients increases, but healthcare resource allocation remains efficient
Solution Approach 1:
The patent implements preliminary genetic testing panels specifically designed for African and mixed-race patients before making diagnostic exclusions. By performing this preliminary racial-specific testing, the system maintains efficient healthcare resource allocation while preventing premature exclusion of CF diagnosis in non-Caucasian patients, thereby preserving both diagnostic reliability and operational productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method and kit provide a molecular basis for accurate CF diagnosis in African and mixed-race patients, overcoming diagnostic biases and increasing mutation detection rates, thereby improving patient outcomes and reducing morbidity and mortality.
Implementation Method 1
providing one or more nucleic acid sequences, fully complementary to one or more segments of the CFTR gene
Implementation Method 2
employing techniques such as ARMS, NGS, qPCR, and microarrays
Implementation Method 3
employing techniques such as ARMS, NGS, qPCR, and microarrays
Data Source
AI summary
This invention relates to a method of identifying mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a kit for performing the method, and furthermore to isolated nucleotide sequences being complementary to one or more mutations of the CFTR gene. According to a first aspect of the invention there is provided a method of identifying mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including the steps of providing one or more nucleic acid sequences, fully complementary to one or more segments of the CFTR gene, wherein the one or more nucleic acid sequences correspond to the mutation to be identified; providing a biological sample of an individual to be tested for CF; isolating nucleic acids from the biological sample; and testing the biological sample for the presence of one or more of the nucleic acid sequences using a suitable detection method.